You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameGlimepiride
Accession NumberDB00222  (APRD00381)
TypeSmall Molecule
GroupsApproved
Description

Glimepiride is the first III generation sulphonyl urea it is a very potent sulphonyl urea with long duration of action.

Structure
Thumb
Synonyms
Amaryl
Glimepirida
Glimépiride
Glimepiridum
External Identifiers Not Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Amaryltablet1 mg/1oralSanofi Aventis U.S. Llc2009-06-18Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Amaryltablet4 mgoralSanofi Aventis Canada Inc2002-03-12Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Amaryltablet2 mgoralSanofi Aventis Canada Inc2002-03-12Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Amaryltablet1 mgoralSanofi Aventis Canada Inc2002-03-12Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Amaryltablet4 mg/1oralSanofi Aventis U.S. Llc2009-06-18Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Amaryltablet2 mg/1oralSanofi Aventis U.S. Llc2009-06-18Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Co Glimepiridetablet1 mgoralCobalt Pharmaceuticals Company2006-04-242012-08-02Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Co Glimepiridetablet4 mgoralCobalt Pharmaceuticals Company2006-04-242012-08-02Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Co Glimepiridetablet2 mgoralCobalt Pharmaceuticals Company2006-04-242012-08-02Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Novo-glimepiridetablet4 mgoralNovopharm Limited2006-03-082015-10-26Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Novo-glimepiridetablet2 mgoralNovopharm Limited2006-03-082015-10-26Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Novo-glimepiridetablet1 mgoralNovopharm Limited2006-03-082015-10-26Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PMS-glimepiridetablet2 mgoralPharmascience Inc2006-08-15Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PMS-glimepiridetablet1 mgoralPharmascience Inc2006-08-15Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PMS-glimepiridetablet4 mgoralPharmascience IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ratio-glimepiridetablet4 mgoralTeva Canada Limited2005-11-22Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ratio-glimepiridetablet2 mgoralTeva Canada Limited2005-11-22Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ratio-glimepiridetablet1 mgoralTeva Canada Limited2005-11-22Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Sandoz Glimepiridetablet3 mgoralSandoz Canada IncorporatedNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Sandoz Glimepiridetablet2 mgoralSandoz Canada Incorporated2005-08-04Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Sandoz Glimepiridetablet1 mgoralSandoz Canada Incorporated2005-08-04Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Sandoz Glimepiridetablet4 mgoralSandoz Canada Incorporated2005-08-04Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-glimepiridetablet2 mgoralApotex Inc2007-09-29Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-glimepiridetablet1 mgoralApotex Inc2007-09-29Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-glimepiridetablet4 mgoralApotex Inc2007-09-29Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Glimepiridetablet2 mg/1oralRebel Distributors Corp2005-10-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet4 mg/1oralSt Marys Medical Park Pharmacy2013-05-09Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet1 mg/1oralInternational Laboratories, Inc.2009-02-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet1 mg/1oralBlue Point Laboratories2014-02-26Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet1 mg/1oralTeva Pharmaceuticals USA Inc2005-10-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet4 mg/1oralPd Rx Pharmaceuticals, Inc.2007-08-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet2 mg/1oralREMEDYREPACK INC.2015-11-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet2 mg/1oralCardinal Health2007-08-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet1 mg/1oralBionpharma Inc.2015-10-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet2 mg/1oralQualitest Pharmaceuticals2010-10-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet1 mg/1oralUnit Dose Services2005-10-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet2 mg/1oralSTAT Rx USA LLC2005-10-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet2 mg/1oralVirtus Pharmaceuticals LLC2013-12-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet1 mg/1oralAccord Healthcare Inc2007-08-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet1 mg/1oralREMEDYREPACK INC.2013-11-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet2 mg/1oralPd Rx Pharmaceuticals, Inc.2005-10-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet2 mg/1oralAurobindo Pharma Limited2012-06-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet4 mg/1oralClinical Solutions Wholesale2005-10-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet1 mg/1oralAvera Mc Kennan Hospital2015-04-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet1 mg/1oralQualitest Pharmaceuticals2010-10-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet4 mg/1oralUnit Dose Services2005-10-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet4 mg/1oralSTAT Rx USA LLC2005-10-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet1 mg/1oralREMEDYREPACK INC.2015-07-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet4 mg/1oralDr. Reddy's Laboratories Limited2005-10-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet1 mg/1oralVirtus Pharmaceuticals LLC2013-12-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet4 mg/1oralBlenheim Pharmacal, Inc.2013-10-08Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet4 mg/1oralREMEDYREPACK INC.2013-05-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet8 mg/1oralMicro Labs Limited2013-06-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet1 mg/1oralAurobindo Pharma Limited2012-06-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet2 mg/1oralClinical Solutions Wholesale2005-10-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet1 mg/1oralAmerican Health Packaging2014-07-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet4 mg/1oralMylan Pharmaceuticals Inc.2006-03-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet2 mg/1oralUnit Dose Services2005-10-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet1 mg/1oralLake Erie Medical DBA Quality Care Products LLC2005-10-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet1 mg/1oralREMEDYREPACK INC.2015-06-05Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet2 mg/1oralDr. Reddy's Laboratories Limited2005-10-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet4 mg/1oralVirtus Pharmaceuticals2015-07-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet2 mg/1oralBlenheim Pharmacal, Inc.2013-10-08Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet2 mg/1oralREMEDYREPACK INC.2013-05-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet6 mg/1oralMicro Labs Limited2013-06-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet2 mg/1oralbryant ranch prepack2005-10-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet4 mg/1oralCitron Pharma LLC2012-06-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet4 mg/1oralAmerican Health Packaging2009-05-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet2 mg/1oralMylan Pharmaceuticals Inc.2006-03-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet4 mg/1oralPerrigo New York Inc2005-10-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet4 mg/1oralAidarex Pharmaceuticals LLC2005-10-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet2 mg/1oralREMEDYREPACK INC.2015-03-16Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet1 mg/1oralDr. Reddy's Laboratories Limited2005-10-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet1 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2005-10-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet4 mg/1oralNorthwind Pharmaceuticals2014-12-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet4 mg/1oralMicro Labs Limited2013-06-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet4 mg/1oralbryant ranch prepack2005-10-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet2 mg/1oralCitron Pharma LLC2012-06-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet2 mg/1oralVirtus Pharmaceuticals2015-07-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet1 mg/1oralMylan Pharmaceuticals Inc.2006-03-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet2 mg/1oralPerrigo New York Inc2005-10-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet2 mg/1oralAidarex Pharmaceuticals LLC2013-06-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet4 mg/1oralCarlsbad Technology, Inc.2012-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet2 mg/1oralPhysicians Total Care, Inc.2005-10-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet2 mg/1oralAmerican Health Packaging2009-05-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet2 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2005-10-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet2 mg/1oralNorthwind Pharmaceuticals, LLC2015-02-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet3 mg/1oralMicro Labs Limited2013-06-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet4 mg/1oralProficient Rx LP2007-08-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet1 mg/1oralCitron Pharma LLC2012-06-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet1 mg/1oralVirtus Pharmaceuticals2015-07-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet4 mg/1oralTeva Pharmaceuticals USA Inc2005-10-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet1 mg/1oralPerrigo New York Inc2005-10-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet1 mg/1oralRebel Distributors Corp2005-10-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet2 mg/1oralCarlsbad Technology, Inc.2012-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet4 mg/1oralPhysicians Total Care, Inc.2005-10-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet4 mg/1oralBlue Point Laboratories2014-02-26Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet4 mg/1oralREMEDYREPACK INC.2016-01-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet2 mg/1oralMicro Labs Limited2013-06-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet4 mg/1oralDIRECT RX2015-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet2 mg/1oralCardinal Health2010-11-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet4 mg/1oralBionpharma Inc.2015-10-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet4 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2005-10-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet4 mg/1oralMylan Institutional Inc.2006-03-27Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet2 mg/1oralMed Vantx, Inc.2012-04-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet2 mg/1oralSt Marys Medical Park Pharmacy2013-05-09Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet4 mg/1oralAccord Healthcare Inc2007-08-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet2 mg/1oralInternational Laboratories, Inc.2009-02-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet4 mg/1oralPd Rx Pharmaceuticals, Inc.2005-10-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet4 mg/1oralRebel Distributors Corp2005-10-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet1 mg/1oralCarlsbad Technology, Inc.2012-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet1 mg/1oralPhysicians Total Care, Inc.2005-10-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet2 mg/1oralBlue Point Laboratories2014-02-26Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet2 mg/1oralTeva Pharmaceuticals USA Inc2005-10-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet2 mg/1oralPd Rx Pharmaceuticals, Inc.2007-08-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet2 mg/1oralDIRECT RX2015-11-24Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet4 mg/1oralCardinal Health2007-08-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet2 mg/1oralBionpharma Inc.2015-10-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet4 mg/1oralQualitest Pharmaceuticals2010-10-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet2 mg/1oralMylan Institutional Inc.2006-03-27Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet1 mg/1oralMicro Labs Limited2013-06-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet4 mg/1oralAurobindo Pharma Limited2012-06-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet1 mg/1oralSt Marys Medical Park Pharmacy2014-05-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet4 mg/1oralVirtus Pharmaceuticals LLC2013-12-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet2 mg/1oralAccord Healthcare Inc2007-08-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet4 mg/1oralInternational Laboratories, Inc.2009-02-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Glimepiridetablet1 mg/1oralPd Rx Pharmaceuticals, Inc.2005-10-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International Brands
NameCompany
GLIMPIDRanbaxy Laboratories
GLIMYDr.Reddy's Labs
Brand mixtures
NameLabellerIngredients
AvandarylGlaxo Smith Kline Llc
DuetactTakeda Pharmaceuticals America, Inc.
Pioglitazone and GlimepiridePrasco Laboratories
Pioglitazone Hydrochloride and GlimepirideSandoz Inc
SaltsNot Available
Categories
UNII6KY687524K
CAS number93479-97-1
WeightAverage: 490.616
Monoisotopic: 490.224990908
Chemical FormulaC24H34N4O5S
InChI KeyInChIKey=WIGIZIANZCJQQY-UHFFFAOYSA-N
InChI
InChI=1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)
IUPAC Name
3-ethyl-4-methyl-N-{2-[4-({[(4-methylcyclohexyl)carbamoyl]amino}sulfonyl)phenyl]ethyl}-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide
SMILES
CCC1=C(C)CN(C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC2CCC(C)CC2)C1=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzenesulfonamides
Direct ParentBenzenesulfonamides
Alternative Parents
Substituents
  • Benzenesulfonamide
  • Phenethylamine
  • Pyrroline carboxylic acid or derivatives
  • Ureide
  • Sulfonylurea
  • Cyclohexylamine
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Pyrroline
  • Urea
  • Tertiary amine
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor concomitant use with insulin for the treatment of noninsulin-dependent (type 2) diabetes mellitus.
PharmacodynamicsGlimepiride, like glyburide and glipizide, is a "second-generation" sulfonylurea agents. Glimepiride is used with diet to lower blood glucose by increasing the secretion of insulin from pancreas and increasing the sensitivity of peripheral tissues to insulin.
Mechanism of actionThe mechanism of action of glimepiride in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Glimepiride likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. This increase in intracellular calcium ion concentration induces the secretion of insulin.
AbsorptionCompletely (100%) absorbed following oral administration.
Volume of distribution
  • 21.8 ± 13.9 L [Volunteers]
  • 19.8 ± 12.7 L [Patients with Type 2 diabetes, Single Dose]
  • 37.1 ± 18.2 L [Patients with Type 2 diabetes, Multiple Dose]
Protein bindingOver 99.5% bound to plasma protein.
Metabolism

Hepatic. Following either an intravenous or oral dose, glimepiride is completely metabolized by oxidative biotransformation to a major metabolite, cyclohexyl hydroxymethyl derivative (M1), via the hepatic cytochrome P450 II C9 subsystem. M1 is further metabolized to the carboxyl derivative (M2) by one or several cytosolic enzymes. M1, but not M2, possessed approximately one third of the pharmacologic activity of its parent in an animal model. However, whether the glucose-lowering effect of M1 is clinically significant is not clear.

SubstrateEnzymesProduct
Glimepiride
Cyclohexyl hydroxymethyl glimepirideDetails
Cyclohexyl hydroxymethyl glimepiride
Cyclohexyl carboxyl glimepirideDetails
Route of eliminationNot Available
Half lifeApproximately 5 hours following single dose.
Clearance
  • 52.1 +/- 16.0 mL/min [Normal subjects with single oral dose]
  • 48.5 +/- 29.3 mL/min [Patients with Type 2 diabetes, with single oral dose]
  • 52.7 +/- 40.3 mL/min [Patients with Type 2 diabetes, with multiple oral dose]
  • 47.8 mL/min [healthy after intravenous (IV) dosing]
ToxicitySevere hypoglycemic reactions with coma, seizure, or other neurological impairment.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.986
Blood Brain Barrier+0.7322
Caco-2 permeable-0.6809
P-glycoprotein substrateSubstrate0.7501
P-glycoprotein inhibitor INon-inhibitor0.6556
P-glycoprotein inhibitor IIInhibitor0.6124
Renal organic cation transporterNon-inhibitor0.8241
CYP450 2C9 substrateSubstrate0.5661
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5978
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8599
Ames testNon AMES toxic0.6392
CarcinogenicityNon-carcinogens0.7301
BiodegradationNot ready biodegradable0.68
Rat acute toxicity2.4158 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7714
hERG inhibition (predictor II)Non-inhibitor0.8263
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Sanofi aventis us llc
  • Accord healthcare inc
  • Carlsbad technology inc
  • Corepharma llc
  • Dr reddys laboratories ltd
  • Genpharm inc
  • Invagen pharmaceuticals inc
  • Mylan pharmaceuticals inc
  • Ranbaxy laboratories ltd
  • Teva pharmaceuticals usa inc
  • Vintage pharmaceuticals llc
  • Watson laboratories inc
  • Watson laboratories inc florida
Packagers
Dosage forms
FormRouteStrength
Tabletoral1 mg/1
Tabletoral1 mg
Tabletoral2 mg
Tabletoral2 mg/1
Tabletoral4 mg
Tabletoral4 mg/1
Tablet, film coatedoral
Tabletoral3 mg/1
Tabletoral6 mg/1
Tabletoral8 mg/1
Tabletoral
Tabletoral3 mg
Prices
Unit descriptionCostUnit
Amaryl 4 mg tablet2.11USD tablet
Amaryl 2 mg tablet1.25USD tablet
Glimepiride 4 mg tablet1.25USD tablet
Amaryl 1 mg tablet0.88USD tablet
Glimepiride 2 mg tablet0.67USD tablet
Glimepiride 1 mg tablet0.42USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point207 °CNot Available
water solubilityInsolubleNot Available
logP3.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0384 mg/mLALOGPS
logP2.82ALOGPS
logP3.12ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)4.32ChemAxon
pKa (Strongest Basic)-3.7ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area124.68 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity129.8 m3·mol-1ChemAxon
Polarizability53.86 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Suresh Kadam, Venkatasubramanian Tarur, Sanjay Naik, Sachin Gavhane, “Process for preparation of substantially pure glimepiride.” U.S. Patent US20070082943, issued April 12, 2007.

US20070082943
General ReferencesNot Available
External Links
ATC CodesA10BB12
AHFS Codes
  • 68:20.20
PDB EntriesNot Available
FDA labelDownload (176 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AcetohexamideAcetohexamide may increase the hypoglycemic activities of Glimepiride.
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Glimepiride.
AlogliptinAlogliptin may increase the hypoglycemic activities of Glimepiride.
AmitriptylineAmitriptyline may increase the hypoglycemic activities of Glimepiride.
AripiprazoleThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Aripiprazole.
Arsenic trioxideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Arsenic trioxide.
ArticaineThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Articaine.
AsenapineThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Asenapine.
AtazanavirThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Atazanavir.
BendroflumethiazideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Bendroflumethiazide.
BetamethasoneThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Betamethasone.
BrexpiprazoleThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Brexpiprazole.
BumetanideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Bumetanide.
BuserelinThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Buserelin.
CanagliflozinCanagliflozin may increase the hypoglycemic activities of Glimepiride.
CarbocisteineThe risk or severity of adverse effects can be increased when Glimepiride is combined with Carbocisteine.
CeritinibThe serum concentration of Glimepiride can be increased when it is combined with Ceritinib.
ChloramphenicolThe metabolism of Glimepiride can be decreased when combined with Chloramphenicol.
ChlorothiazideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Chlorothiazide.
ChlorpropamideChlorpropamide may increase the hypoglycemic activities of Glimepiride.
ChlorthalidoneThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Chlorthalidone.
CimetidineThe serum concentration of Glimepiride can be increased when it is combined with Cimetidine.
ClozapineThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Clozapine.
ColesevelamThe serum concentration of Glimepiride can be decreased when it is combined with Colesevelam.
CorticotropinThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Corticotropin.
Cortisone acetateThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Cortisone acetate.
Cyproterone acetateThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Cyproterone acetate.
DabrafenibThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Dabrafenib.
DanazolThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Danazol.
DarunavirThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Darunavir.
DesogestrelThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Desogestrel.
DexamethasoneThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Dexamethasone.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Glimepiride.
DiazoxideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Diazoxide.
DicoumarolGlimepiride may increase the anticoagulant activities of Dicoumarol.
DienogestThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Dienogest.
DihydrotestosteroneDihydrotestosterone may increase the hypoglycemic activities of Glimepiride.
DisopyramideGlimepiride may increase the hypoglycemic activities of Disopyramide.
DrospirenoneThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Drospirenone.
EpinephrineThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Epinephrine.
ErythromycinGlimepiride may increase the hypoglycemic activities of Erythromycin.
EstradiolThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Estradiol.
EstropipateThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Estropipate.
Ethacrynic acidThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Ethacrynic acid.
EthanolThe risk or severity of adverse effects can be increased when Glimepiride is combined with Ethanol.
Ethinyl EstradiolThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Ethinyl Estradiol.
EthynodiolThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Ethynodiol.
EtonogestrelThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Etonogestrel.
EverolimusThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Everolimus.
ExenatideExenatide may increase the hypoglycemic activities of Glimepiride.
FenofibrateFenofibrate may increase the hypoglycemic activities of Glimepiride.
FloxuridineThe metabolism of Glimepiride can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Glimepiride can be decreased when combined with Fluconazole.
FludrocortisoneThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Fludrocortisone.
FosamprenavirThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Fosamprenavir.
FurosemideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Furosemide.
GliclazideGliclazide may increase the hypoglycemic activities of Glimepiride.
GlipizideGlimepiride may increase the hypoglycemic activities of Glipizide.
GliquidoneGliquidone may increase the hypoglycemic activities of Glimepiride.
GlyburideGlyburide may increase the hypoglycemic activities of Glimepiride.
GoserelinThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Goserelin.
HistrelinThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Histrelin.
HydrochlorothiazideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Hydrochlorothiazide.
HydrocortisoneThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Hydrocortisone.
Hydroxyprogesterone caproateThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Hydroxyprogesterone caproate.
IloperidoneThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Iloperidone.
IndapamideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Indapamide.
IndinavirThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Indinavir.
inhaled insulinGlimepiride may increase the hypoglycemic activities of inhaled insulin.
Insulin AspartInsulin Aspart may increase the hypoglycemic activities of Glimepiride.
Insulin degludecGlimepiride may increase the hypoglycemic activities of Insulin degludec.
Insulin DetemirInsulin Detemir may increase the hypoglycemic activities of Glimepiride.
Insulin GlargineGlimepiride may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineInsulin Glulisine may increase the hypoglycemic activities of Glimepiride.
Insulin LisproGlimepiride may increase the hypoglycemic activities of Insulin Lispro.
Insulin RegularGlimepiride may increase the hypoglycemic activities of Insulin Regular.
Insulin, isophaneInsulin, isophane may increase the hypoglycemic activities of Glimepiride.
LanreotideGlimepiride may increase the hypoglycemic activities of Lanreotide.
LeuprolideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Leuprolide.
LevonorgestrelThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Levonorgestrel.
LinagliptinLinagliptin may increase the hypoglycemic activities of Glimepiride.
Lipoic AcidLipoic Acid may increase the hypoglycemic activities of Glimepiride.
LopinavirThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Lopinavir.
LumacaftorThe serum concentration of Glimepiride can be decreased when it is combined with Lumacaftor.
LurasidoneThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Lurasidone.
MecamylamineThe risk or severity of adverse effects can be increased when Glimepiride is combined with Mecamylamine.
MecaserminGlimepiride may increase the hypoglycemic activities of Mecasermin.
Medroxyprogesterone AcetateThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Medroxyprogesterone Acetate.
Megestrol acetateThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Megestrol acetate.
MestranolThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Mestranol.
MetforminMetformin may increase the hypoglycemic activities of Glimepiride.
MethotrimeprazineThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Methotrimeprazine.
MethyclothiazideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Methyclothiazide.
MethylprednisoloneThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Methylprednisolone.
MetolazoneThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Metolazone.
MetreleptinMetreleptin may increase the hypoglycemic activities of Glimepiride.
MiconazoleMiconazole may increase the hypoglycemic activities of Glimepiride.
MifepristoneThe serum concentration of Glimepiride can be increased when it is combined with Mifepristone.
NadololNadolol may increase the hypoglycemic activities of Glimepiride.
NateglinideGlimepiride may increase the hypoglycemic activities of Nateglinide.
NelfinavirThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Nelfinavir.
NiacinThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Niacin.
NilotinibThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Nilotinib.
NorethindroneThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Norethindrone.
NorgestimateThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Norgestimate.
OctreotideGlimepiride may increase the hypoglycemic activities of Octreotide.
OlanzapineThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Olanzapine.
OxandroloneOxandrolone may increase the hypoglycemic activities of Glimepiride.
PaliperidoneThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Paliperidone.
ParoxetineParoxetine may increase the hypoglycemic activities of Glimepiride.
PasireotideGlimepiride may increase the hypoglycemic activities of Pasireotide.
PegvisomantPegvisomant may increase the hypoglycemic activities of Glimepiride.
PentamidineGlimepiride may increase the hypoglycemic activities of Pentamidine.
PhenelzinePhenelzine may increase the hypoglycemic activities of Glimepiride.
PhenytoinThe metabolism of Glimepiride can be increased when combined with Phenytoin.
PipotiazineThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Pipotiazine.
PorfimerGlimepiride may increase the photosensitizing activities of Porfimer.
PrednisoloneThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Prednisolone.
PrednisoneThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Prednisone.
ProbenecidThe protein binding of Glimepiride can be decreased when combined with Probenecid.
ProgesteroneThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Progesterone.
QuetiapineThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Quetiapine.
QuinineGlimepiride may increase the hypoglycemic activities of Quinine.
RanitidineThe serum concentration of Glimepiride can be increased when it is combined with Ranitidine.
RepaglinideRepaglinide may increase the hypoglycemic activities of Glimepiride.
Repository corticotropinThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Repository corticotropin.
RifampicinThe serum concentration of Glimepiride can be decreased when it is combined with Rifampicin.
RisperidoneThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Risperidone.
RitonavirThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Ritonavir.
Salicylate-sodiumSalicylate-sodium may increase the hypoglycemic activities of Glimepiride.
SaquinavirThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Saquinavir.
SaxagliptinSaxagliptin may increase the hypoglycemic activities of Glimepiride.
SecobarbitalThe metabolism of Glimepiride can be increased when combined with Secobarbital.
SirolimusThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Sirolimus.
SitagliptinSitagliptin may increase the hypoglycemic activities of Glimepiride.
SparfloxacinSparfloxacin may increase the hypoglycemic activities of Glimepiride.
SulfadiazineGlimepiride may increase the hypoglycemic activities of Sulfadiazine.
SulfamethoxazoleGlimepiride may increase the hypoglycemic activities of Sulfamethoxazole.
SulfisoxazoleGlimepiride may increase the hypoglycemic activities of Sulfisoxazole.
SunitinibGlimepiride may increase the hypoglycemic activities of Sunitinib.
TacrolimusThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Tacrolimus.
TemsirolimusThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Temsirolimus.
TestosteroneTestosterone may increase the hypoglycemic activities of Glimepiride.
TipranavirThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Tipranavir.
TolazamideGlimepiride may increase the hypoglycemic activities of Tolazamide.
TolbutamideTolbutamide may increase the hypoglycemic activities of Glimepiride.
TorasemideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Torasemide.
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Glimepiride.
TriamcinoloneThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Triamcinolone.
TrichlormethiazideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Trichlormethiazide.
TrimethoprimGlimepiride may increase the hypoglycemic activities of Trimethoprim.
TriptorelinThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Triptorelin.
TroglitazoneTroglitazone may increase the hypoglycemic activities of Glimepiride.
VerteporfinGlimepiride may increase the photosensitizing activities of Verteporfin.
VildagliptinVildagliptin may increase the hypoglycemic activities of Glimepiride.
VoriconazoleThe serum concentration of Glimepiride can be increased when it is combined with Voriconazole.
VorinostatThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Vorinostat.
ZiprasidoneThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Ziprasidone.
Food Interactions
  • Avoid alcohol.
  • Even though food reduces product absorption, the manufacturer recommends taking the product with the first meal of the day.

Targets

1. ATP-sensitive inward rectifier potassium channel 11

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
ATP-sensitive inward rectifier potassium channel 11 Q14654 Details

References:

  1. Song DK, Ashcroft FM: Glimepiride block of cloned beta-cell, cardiac and smooth muscle K(ATP) channels. Br J Pharmacol. 2001 May;133(1):193-9. Pubmed
  2. Lawrence CL, Rainbow RD, Davies NW, Standen NB: Effect of metabolic inhibition on glimepiride block of native and cloned cardiac sarcolemmal K(ATP) channels. Br J Pharmacol. 2002 Jul;136(5):746-52. Pubmed
  3. Bataille D: [Molecular mechanisms of insulin secretion]. Diabetes Metab. 2002 Dec;28(6 Suppl):4S7-13. Pubmed

2. ATP-sensitive inward rectifier potassium channel 1

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
ATP-sensitive inward rectifier potassium channel 1 P48048 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Proks P, Reimann F, Green N, Gribble F, Ashcroft F: Sulfonylurea stimulation of insulin secretion. Diabetes. 2002 Dec;51 Suppl 3:S368-76. Pubmed
  4. Bataille D: [Molecular mechanisms of insulin secretion]. Diabetes Metab. 2002 Dec;28(6 Suppl):4S7-13. Pubmed

3. ATP-binding cassette sub-family C member 8

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: inducer

Components

Name UniProt ID Details
ATP-binding cassette sub-family C member 8 Q09428 Details

References:

  1. Muller G, Hartz D, Punter J, Okonomopulos R, Kramer W: Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. I. Binding characteristics. Biochim Biophys Acta. 1994 May 11;1191(2):267-77. Pubmed
  2. Kramer W, Muller G, Geisen K: Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at beta-cells. Horm Metab Res. 1996 Sep;28(9):464-8. Pubmed
  3. Kramer W, Muller G, Girbig F, Gutjahr U, Kowalewski S, Hartz D, Summ HD: The molecular interaction of sulfonylureas with beta-cell ATP-sensitive K(+)-channels. Diabetes Res Clin Pract. 1995 Aug;28 Suppl:S67-80. Pubmed

Enzymes

1. Cytochrome P450 2C9

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2C9 P11712 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 25, 2013 14:06